Innovative Therapeutics in Oncology and Neuroscience

25 ZEJULA Favorable Overall Survival (OS) Trend in All Patient Groups Compared with Placebo (NORA Study) Approved China NORA Phase 3 Study - Interim OS Analysis at 2022 ESMO Virtual Plenary 1,2 OS in the ITT Population OS Subgroup Analysis in gBRC Amut OS Subgroup Analysis in non-gBRCAmut Median OS (months) Niraparib (n=177) Placebo (n=88) Median OS (months) Niraparib (n=65) Placebo (n=35) Median OS (months) Niraparib (n=112) Placebo (n=53) Months (95% CI) 46.32 (41.03-NE) (33.08-NE) 43.37 Months (95% CI) NR (35.38-NE) 47.61 (31.57-NE) Months (95% CI) 43.10 (38.41-NE) 38.41 (29.54-NE) Hazard Ratio (95% CI) Hazard Ratio (95% CI) 0.76 (0.40-1.46) Hazard Ratio (95% CI) 0.86 (0.53-1.38) Once-daily oral Zejula niraparib capsules 100 mg 0.82 (0.56-1.21) Key Conclusion ZEJULA maintenance treatment using an individualized starting dose (ISD) regimen provides a favorable OS trend irrespective of gBRCA status compared with placebo • Next Steps & Core Opportunity Full OS analysis of the NORA study is expected at an upcoming medical conference in 2024 ⚫ Zai Lab independently conducted the PRIME study for first-line ovarian cancer in China Abbreviations: overall survival (OS), intention to treat (ITT), confidence interval (CI), not evaluable (NE), not reached (NR). Sources: Zai Lab presentation at 2022 ESMO Virtual Plenary; Globocan, 2020. Notes: (1) Ad hoc Interim Overall Survival Results of Niraparib with Individualized Starting Dose as Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer (NORA): A Double-blind, Randomized, Placebo-controlled, Phase 3 trial; Data cutoff date was September 23, 2022; (2) Median follow-up time for OS in niraparib and placebo arm was 45.7 and 44.5 months. Clinical Data - Oncology

View entire presentation